Results 141 to 150 of about 4,894,740 (406)

Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer

Nature Network Boston, 2022
W. Chatila, Jin K. Kim, H. Walch, Michael R. Marco, Ching-Tung Chen, Fan Wu, D. Omer, D. Khalil, K. Ganesh, X. Qu, A. Luthra, Seo-Hyun Choi, Yu-jui Ho, Ritika Kundra, Katharine I Groves, O. Chow, A. Cercek, M. Weiser, M. Widmar, I. Wei, E. Pappou, G. Nash, P. Paty, Q. Shi, E. Vakiani, S. Duygu Selcuklu, M. Donoghue, D. Solit, M. Berger, J. Shia, Raphael A. Pelossof, P. Romesser, R. Yaeger, J. Smith, N. Schultz, F. Sánchez-Vega, J. García-Aguilar   +36 more
semanticscholar   +1 more source

Association Between Adjuvant Chemotherapy and Overall Survival in Patients With Rectal Cancer and Pathological Complete Response After Neoadjuvant Chemotherapy and Resection

JAMA Oncology, 2018
Importance Although American guidelines recommend use of adjuvant chemotherapy in patients with locally advanced rectal cancer, individuals who achieve a pathological complete response (pCR) following neoadjuvant chemoradiotherapy are less likely to ...
F. Dossa, S. Acuna, A. Rickles, M. Berho, S. Wexner, F. Quereshy, N. Baxter, S. Chadi   +7 more
semanticscholar   +1 more source

Identification of TPRA1 as a Novel Receptor and Predictive Biomarker for Oncolytic Virus M1

Advanced Science, EarlyView.
This study identifies transmembrane protein adipocyte‐associated 1 (TPRA1) as a novel receptor for oncolytic virus M1 (OVM). TPRA1's ectodomain binds OVM particles, while its intracellular domain facilitates virus internalization, promoting efficient viral entry.
Linyi Hu, Guigen Zhang, Yuan Lin, Shiming Yi, Jingyu Yang, Xueying Lin, Deli Song, Zhiheng Liu, Jiayu Zhang, Ying Zeng, Shanyu Huang, Zhen Fan, Jifu Zhang, Ying Liu, Cheng Hu, Wenbo Zhu, Wei Yin, Jun Hu, Guangmei Yan, Jing Cai, Jiankai Liang   +20 more
wiley   +1 more source

Tumour invasiveness, the local and systemic environment and the basis of staging systems in colorectal cancer [PDF]

, 2017
background: The present study aimed to examine the relationship between tumour invasiveness (T stage), the local and systemic environment and cancer-specific survival (CSS) of patients with primary operable colorectal cancer.
A Chrysanthopoulou, A Huijbers, AJ Munro, B Mlecnik, C Guastadisegni, C S D Roxburgh, CE Dukes, CH Richards, D C McMillan, D Church, D Hanahan, DC McMillan, F Pages, F Pages, FA Sinicrope, G Bindea, GJ Guthrie, H Ueno, H Ueno, H van Wyk, HC van Wyk, ID Nagtegaal, J Edwards, J Galon, J Guinney, J H Park, J Li, JB O'Connell, JH Park, JH Park, JH Park, JH Park, K Birkenkamp-Demtroder, K Klintrup, L De Smedt, LL Gunderson, LS Rozek, MJ Pollheimer, P G Horgan, P Quirke, R Salazar, S Ogino, SA Vayrynen, SS McAllister, T Kantola, VH Koelzer, W De Roock, WE Mesker   +47 more
core   +1 more source

Effects of metformin and phenformin on apoptosis and epithelial‐mesenchymal transition in chemoresistant rectal cancer

Cancer Science, 2019
Recurrence and chemoresistance in colorectal cancer remain important issues for patients treated with conventional therapeutics. Metformin and phenformin, previously used in the treatment of diabetes, have been shown to have anticancer effects in various
Ji-Hye Park, Young-Heon Kim, E. H. Park, Sun-Joo Lee, Hyewon Kim, A. Kim, Seung Bum Lee, Sehwan Shim, H. Jang, J. Myung, Sunhoo Park, Su-Jae Lee, M. J. Kim   +12 more
semanticscholar   +1 more source

Aloe‐Emodin Targeting FOXC2 Disrupts NETs Formation and EMT‐Driven Postoperative Peritoneal Adhesion Through TGF‐β1‐Smad2/3 Pathway

Advanced Science, EarlyView.
Forkhead box protein C2 (FOXC2) is highlighted as a pivotal effector in postoperative peritoneal adhesion (PPA) formation. Mechanically, FOXC2 mediates NETs‐induced EMT alterations through the TGF‐β1‐Smad2/3 pathway. Aloe‐emodin (AE) ameliorates FOXC2‐driven fibrosis by blocking NETs formation and EMT changes through this pathway.
Lili Yang, Yunda Fang, Yuheng Lian, Ziyang Kong, Jia Miao, Yanqi Chen, Wen Li, Feiyan Chen, Bin Zhang, Yao Chen, Yaoyao Bian   +10 more
wiley   +1 more source

High dose rate brachytherapy as monotherapy for localised prostate cancer : a hypofractionated two-implant approach in 351 consecutive patients [PDF]

, 2013
BACKGROUND: To report the clinical outcome of high dose rate brachytherapy as sole treatment for clinically localised prostate cancer. METHODS: Between March 2004 and January 2008, a total of 351 consecutive patients with clinically localised prostate ...
Baltas, Dimos, Chatzikonstantinou, Georgios, Milickovic, Natasa, Ratka, Markus, Tselis, Nikolaos, Tunn, Ulf W., Zamboglou, Nikolaos   +6 more
core   +1 more source

Immediate results of combined and multivisceral resections for rectal cancer

Сибирский онкологический журнал, 2019
Background. Currently, the indications for multivisceral pelvic resections have increased dramatically. However, short-and long-term outcomes after these resections for locally advanced rectal cancer remain a subject of debate.The purpose of the study ...
S. G. Afanasyev, A. Yu. Dobrodeev, I. B. Khadagaev, S. A. Fursov, E. A. Usynin, А. S. Tarasova, D. A. Sorokin, V. V. Faltin, A. V. Usova   +8 more
doaj   +1 more source

Changing outcomes following pelvic exenteration for locally advanced and recurrent rectal cancer

BJS Open, 2019
Pelvic exenteration for locally advanced rectal cancer (LARC) and locally recurrent rectal cancer (LRRC) is technically challenging but increasingly performed in specialist centres. The aim of this study was to compare outcomes of exenteration over time.
M. E. A. G. J. N. Abdul M. W. A. K. K. R. M. G. B. K. Kelly Aalbers Aziz Abraham‐Nordling Alberda Antoni, M. Kelly, A. Aalbers, N. A. Aziz, M. Abraham-Nordling, W. Alberda, A. Antoniou, K. Austin, R. Baker, M. Bali, G. Baseckas, B. Bednarski, G. Beets, P. Berg, J. Beynon, S. Biondo, L. Bordeianou, M. Brunner, P. Buchwald, J. Burger, D. Burling, N. Campain, K. Chan, G. Chang, M. Chew, P. Chong, H. Christensen, M. Codd, A. Colquhoun, A. Corr, M. Coscia, P. Coyne, B. Creavin, L. Damjanović, I. Daniels, M. Davies, R. Davies, J. de Wilt, Q. Denost, C. Deutsch, D. Dietz, E. Dozois, M. Duff, T. Eglinton, M. Evans, M. Evans, N. Fearnhead, F. Frizelle, E. García-Granero, J. L. García-Sabrido, L. Gentilini, M. George, R. Glynn, T. Golda, B. Griffiths, J. Hagemans, D. Harji, D. Harris, A. Heriot, W. Hohenberger, T. Holm, J. Jenkins, Y. Kanemitsu, S. Kapur, D. Keller, S. Kelley, H. Kim, C. Koh, N. Kok, R. Kokelaar, C. Kontovounisios, M. Kusters, D. Larson, S. Laurberg, W. Law, P. Lee, M. Lydrup, A. Lynch, A. Martling, K. Mathis, W. Meijerink, A. Mentha, S. Merkel, F. McDermott, J. McGrath, A. Mihailo, A. Mirnezami, J. Morton, T. Mullaney, M. Nielsen, G. Nieuwenhuijzen, P. Nilsson, P. O'Connell, G. Palmer, D. Patsouras, G. Pellino, G. Poggioli, M. Quinn, A. Quyn, R. Radwan, S. Rasheed, P. Rasmussen, R. Rocha, J. Rothbarth, C. Roxburgh, H. Rutten, É. Ryan, P. Sagar, T. Sammour, A. Schizas, E. Schwarzkopf, V. Scripcariu, I. Shaikh, D. Shida, A. Simpson, N. Smart, J. Smith, M. Solomon, M. M. Sørensen, S. Steele, D. Steffens, L. Stocchi, N. Stylianides, C. Taylor, P. Tekkis, S. Tsukamoto, W. H. Turner, J. Tuynman, G. V. van Ramshorst, D. V. van Zoggel, W. Vasquez‐Jimenez, C. Verhoef, M. Verstegen, C. Wakeman, S. Warrier, H. Wasmuth, M. Weiser, J. Wheeler, J. Wild, D. Winter, J. Yip   +140 more
semanticscholar   +1 more source

Preoperative Versus Postoperative Chemotherapy With CAPOX Plus Bevacizumab for Resectable Colorectal Liver Metastases: A Randomized Phase II Trial (HiSCO‐01)

Annals of Gastroenterological Surgery, EarlyView.
Our aim was to compare the outcomes of preoperative chemotherapy with postoperative chemotherapy in patients with resectable colorectal liver metastases treated with CAPOX‐Bev. We demonstrated that both preoperative and postoperative CAPOX‐Bev were safely administered, and preoperative chemotherapy showed a numerically higher treatment compliance rate ...
Yuji Takakura, Katsunori Shinozaki, Satoshi Ikeda, Hiroyuki Egi, Yuzo Hirata, Manabu Shimomura, Takafumi Oshiro, Takao Hinoi, Daisuke Sumitani, Masahiro Nakahara, Masanori Yoshimitsu, Naruhiko Honmyo, Tsuyoshi Kobayashi, Junko Tanaka, Hideki Ohdan, on behalf of the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)   +15 more
wiley   +1 more source